Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses
about
Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityInduction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine designSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusNeutralizing antibody response and SARS severityRespiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2.Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.Mucosal vaccines against respiratory syncytial virusRespiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1Current concepts and progress in RSV vaccine development.Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticlesMammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractLong-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomainsNeonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infantsSingle intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infectionRespiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gutThe role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Respiratory syncytial virus--a comprehensive review.Central nervous system alterations caused by infection with the human respiratory syncytial virus.Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.Inhibition of Respiratory Syncytial Virus Replication by Simultaneous Targeting of mRNA and Genomic RNA Using Dual-Targeting siRNAs.Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
P2860
Q27010165-9763D148-26C1-4765-934C-6949870C1C2FQ27021304-E8E08917-96CD-45D7-8EC8-1794F0FC54ACQ28067143-C088EA2C-FC01-4CA1-978F-4D8CE2BDFAA0Q28385241-075EBB6E-CC87-4D06-88FC-BDC0160AEC78Q30425776-CBB9A963-87BD-4B35-B3D6-B6A203D9EF99Q30485791-684DCCD4-9AE7-41D1-B2F3-B4FCB1317842Q33813095-17E8DA8E-BF24-46CA-B9DF-CC16E744D1B7Q33837530-E66A759E-5F21-46BF-8AE7-618EDB4C9E55Q33964142-1AE4AE4D-7D95-4E2B-9F55-8CC3A6FDF0B9Q34175747-A2C600D2-F382-4A29-949F-FAE99EB5342FQ34396689-C8961176-342E-4563-9C0A-7ED0186FEE93Q34661842-1B5EFB8C-A4A7-4702-9ABE-141A86A65D2CQ35690781-8BC0F69C-818A-4DE1-9B6A-D7FD2054EE5AQ36363325-EF83EA4F-BE30-42C0-9899-D5CF7E96B087Q36482799-0F1688AB-B69B-4ED4-9196-625EE84FC3D2Q36483809-432DE38F-1B7D-4B79-A1CA-47E758E8BB8BQ36530226-789A2DEC-082D-464A-8A05-471E5983D15BQ36810987-54255BEC-915B-452C-878C-AC415A1031C0Q36947774-9734048C-B177-480A-AC69-13E430F5E43FQ37071608-EFB44716-1086-45DC-8BDB-0937ADF12919Q37412509-F83700AD-2629-4E70-AC56-523C5F1FA09EQ37615056-8DB6F7EF-57B4-4674-9231-9FC68D26346DQ38068469-FF62B2FC-42A9-4B83-A926-824630C2CE8CQ38098094-0E8E1046-7C70-4CD6-8CBE-FAF3D20396D4Q38260281-5281DB82-583D-436C-A81D-60D356AF5D87Q39027049-2D3398B6-E4D6-44CA-B5A2-D48662C86A4BQ40021220-C36598BC-06AE-4F73-AA36-52E216E599E6Q40476115-2F0A8555-DEF4-4051-A6CA-73FE2E4ADE50Q52649839-B9E4C740-79C9-4608-8AAE-4A107D6D4F06
P2860
Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Inability to evoke a long-last ...... ctive nasal antibody responses
@ast
Inability to evoke a long-last ...... ctive nasal antibody responses
@en
type
label
Inability to evoke a long-last ...... ctive nasal antibody responses
@ast
Inability to evoke a long-last ...... ctive nasal antibody responses
@en
prefLabel
Inability to evoke a long-last ...... ctive nasal antibody responses
@ast
Inability to evoke a long-last ...... ctive nasal antibody responses
@en
P2093
P2860
P1433
P1476
Inability to evoke a long-last ...... ctive nasal antibody responses
@en
P2093
Lisa Hyland
Nathalie Etchart
Richard Singleton
P2860
P304
11303-11311
P356
10.1128/JVI.77.21.11303-11311.2003
P407
P577
2003-11-01T00:00:00Z